Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refractory Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

NCT07738822 is registered in ClinicalTrials.gov with Cullinan Therapeutics Inc. as lead sponsor.

NCT NCT07738822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07738822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refractory Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia
Lead sponsor
Cullinan Therapeutics Inc.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
January 31, 2031
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia (itp), warm autoimmune hemolytic anemia (waiha)